

(19)  **Canadian
Intellectual Property
Office**

An Agency of
Industry Canada

**Office de la Propriété
Intellectuelle
du Canada**

Un organisme
d'Industrie Canada

(11) **CA 2 223 643**

(13) **C**

(40) 23.12.2003

(43) 06.02.1997

(45) 23.12.2003

138

(12)

(21) **2 223 643**

(22) **15.07.1996**

(51) Int. Cl.⁶: **A61K 31/445, A61K 9/22,
A61K 9/28**

(85) **08.01.1998**

(86) **PCT/GB96/01690**

(87) **WO97/003673**

(30) **9514451.5 GB 14.07.1995**

(73)

**MEDEVA EUROPE LIMITED
10 St. Jame's Street SW1A
1EF LONDON XX (GB).**

(72)

**BAKER, HELEN FRANCES (GB).
GILBERT, JULIAN CLIVE (GB).**

(74)

BORDEN LADNER GERVAIS LLP

(54) **PREPARATION DE D-THREO-METHYLPHENIDATE A LIBERATION PROLONGEE**
(54) **SUSTAINED-RELEASE FORMULATION OF D-THREO-METHYLPHENIDATE**

(57)

**A sustained-release formulation of d-threo-
methylphenidate (dtmp).**



Office de la Propriété
Intellectuelle
du Canada

Un organisme
d'Industrie Canada

Canadian
Intellectual Property
Office

An agency of
Industry Canada

CA 2223643 C 2003/12/23

(11)(21) **2 223 643**

(12) **BREVET CANADIEN
CANADIAN PATENT**

(13) **C**

(86) Date de dépôt PCT/PCT Filing Date: 1996/07/15
(87) Date publication PCT/PCT Publication Date: 1997/02/06
(45) Date de délivrance/Issue Date: 2003/12/23
(85) Entrée phase nationale/National Entry: 1998/01/08
(86) N° demande PCT/PCT Application No.: GB 1996/001690
(87) N° publication PCT/PCT Publication No.: 1997/003673
(30) Priorité/Priority: 1995/07/14 (9514451.5) GB

(51) Cl.Int.⁶/Int.Cl.⁶ A61K 31/445, A61K 9/28, A61K 9/22
(72) Inventeurs/Inventors:
BAKER, HELEN FRANCES, GB;
GILBERT, JULIAN CLIVE, GB
(73) Propriétaire/Owner:
MEDEVA EUROPE LIMITED, GB
(74) Agent: BORDEN LADNER GERVAIS LLP

(54) Titre : PREPARATION DE D-THREO-METHYLPHENIDATE A LIBERATION PROLONGEE
(54) Title: SUSTAINED-RELEASE FORMULATION OF D-THREO-METHYLPHENIDATE

(57) Abrégé/Abstract

A sustained-release formulation of d-threo-methylphenidate (dtmp).

Canada

<http://opic.gc.ca> • Ottawa-Hull K1A 0C9 • <http://cipo.gc.ca>

OPIC • CIPQ 191

OPIC



CIPQ

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/445	A1	(11) International Publication Number: WO 97/03673 (43) International Publication Date: 6 February 1997 (06.02.97)
(21) International Application Number: PCT/GB96/01690 (22) International Filing Date: 15 July 1996 (15.07.96) (30) Priority Data: 9514451.5 14 July 1995 (14.07.95) GB (71) Applicant: CHIROSCIENCE LIMITED [GB/GB]; Cambridge Science Park, Milton Road, Cambridge CB4 4WE (GB). (72) Inventors: BAKER, Helen, Frances; Chiroscience Limited, Cambridge Science Park, Milton Road, Cambridge CB4 4WE (GB). GILBERT, Julian, Clive; Chiroscience Limited, Cambridge Science Park, Milton Road, Cambridge CB4 4WE (GB). (74) Agent: GILL JENNINGS & EVERY; Broadgate House, 7 Eldon Street, London EC2M 7LH (GB).		(81) Designated States: AL, AM, AU, AZ, BB, BG, BR, BY, CA, CN, CZ, EE, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: SUSTAINED-RELEASE FORMULATION OF D-THREO-METHYLPHENIDATE (57) Abstract A sustained-release formulation of <i>d-threo</i> -methylphenidate (dtmp).		

SUSTAINED RELEASE FORMULATION OF D-THREO-METHYLPHENIDATE**Field of the Invention**

This invention relates to a sustained-release formulation of methylphenidate.

5 Background of the Invention

Methylphenidate is a known drug. It is used primarily to treat hyperactive children. It is a controlled substance.

10 Methylphenidate is a chiral molecule. The properties of the enantiomers have been investigated to some extent, although the drug is still administered as the racemate. It is generally thought that *d*-threo-methylphenidate (abbreviated herein as dtmp) is the active material, and that its antipode (ltmp) is metabolised more rapidly.

15 Methylphenidate is often administered in a sustained-release formulation. For example, a coated tablet comprising racemic methylphenidate is administered, with a view to maintaining a therapeutically-effective level of the drug in circulation. This formulation does not provide
20 satisfactory or reproducible dosing.

Srinivas et al, Pharmaceutical Research 10(1):14 (1993), disclose a further disadvantage of known methylphenidate sustained-release formulations, i.e. that serum levels of the drug are increased by chewing. Many
25 children chew tablets, and are therefore liable to receive an unnecessarily high dose of a controlled substance.

Patrick et al, Biopharmaceutics and Drug Disposition 10:165-171 (1989), describe the absorption of sustained-release methylphenidate formulations compared to an
30 immediate-release formulation. It is suggested that the optimum dosage of methylphenidate for children is 0.5-0.7 mg/kg/day.

Summary of the Invention

35 The present invention is based on an appreciation of the fact that, although it is possible to provide a model of chiral drug distribution, and measure the concentration of individual enantiomers and their breakdown products in

a subject, over time, this is a poor model for understanding the effectiveness of the enantiomers. Since, after an initial period, the sustained-release formulation should ideally release the active material as evenly as possible, the administration of a racemate, i.e. of two related compounds, takes no account of interaction between the enantiomers. According to this invention, it has surprisingly been found both that there is considerable interaction, and that dtmp provides relatively linear kinetics within the clinically effective dose range in a suitable model, and is therefore suitable for incorporation in a sustained-release formulation. The experiments and data on which this discovery is based are given below.

Description of the Invention

According to one aspect of the present invention, there is provided a sustained-release formulation of d-threo-methylphenidate (dtmp) substantially free of l-threo-methylphenidate.

According to a further aspect of the present invention, there is provided a use for treating a human subject having a disorder capable of treatment with methylphenidate, of a sustained-release formulation comprising an effective amount of d-threo-methylphenidate, wherein said sustained-release formulation is substantially free of l-threo-methylphenidate.

According to another aspect of the present invention, there is provided a use for treating a human subject having a disorder capable of treatment with methylphenidate, a sustained-release formulation comprising an effective amount of d-threo-methylphenidate, wherein said sustained-release formulation is substantially free of l-threo-methylphenidate, and wherein said effective amount of d-threo-methylphenidate administered to said subject is about 16 to 140 ng.h/ml.

The dtmp that is used in this invention, is substantially free of its antipode (ltmp), e.g. in an enantiomeric excess (ee) of at least 70%, preferably at least 90%, and more preferably at least 95%. The dtmp may be substantially

enantio pure. It may be used in the form of any suitable salt, e.g. the hydrochloride.

The dtmp may be administered by the same means as is known for racemic methylphenidate, in a sustained-release formulation, e.g. a coated tablet. It may be administered in any other conventional sustained-release formulation, via any suitable route of administration. Conventional dosing parameters may be adopted, i.e. those which are known to or adapted to the practice of those skilled in the art.

Compositions of the invention may be administered for known purposes, e.g. the treatment of attention-deficient hyperactivity disorder (ADHD; this term is used herein to encompass attention-deficit disorder) in pre-pubertal children and adults, as a stimulant in cancer patients treated with narcotic analgesics, and also for the treatment of depression (e.g. in AIDS patients), compulsive shopping disorder, narcolepsy and hypersomnia. By contrast to known formulations of methylphenidate, the present invention may have any or all of the following advantages: linear kinetics within the clinically effective dose range, the reduction of exposure to a controlled substance, reduced side-effects (which include anorexia, insomnia, stomach ache and headache), reduced abuse potential, reduced C_{max} , a reduced level of active material even when chewed, reduced patient variability, reduced interaction with ltmp or other drugs, and less variability between fed and fasted subjects.

By controlling the nature of the formulation, it is possible to control dissolution in vitro, and thus match or exceed the US National Formulary (NF) drug release profile for methylphenidate hydrochloride. Further, when administered to a healthy subject, a serum level of dtmp can be attained that is at least 50% of C_{max} , over a period of at least 8 hours, e.g. 8-16, 8-12 or 8-10 hours. Thus, for example, a shorter release period may be preferred or a different period before the serum level drops below a different proportion of C_{max} .

The serum level may be also controlled so that it remains high during the day, after taking a dosage in the morning, and is reduced in the evening, before it can have any undesirable effect on sleeping patterns. Preferably, the serum level is at least 50% C_{max} after 8 hours and less than 25% C_{max} after 12 to 16 hours. Such amounts are, for example, less than 1 mg/kg/day or less than 0.5 mg/kg/day.

Preferably the formulation is one which on administration to a healthy subject, would provide a C_{max} of 2 to 20 ng/ml at a dosage of at least 2 mg.

A formulation of the invention may be a unit dosage such as a tablet, capsule or suspension. It may be in matrix, coating, reservoir, osmotic, ion-exchange or density exchange form. It may comprise a soluble polymer coating which is dissolved or eroded, after administration. The dtmp may be micronised. Alternatively, there may be an insoluble coating, e.g. of a polymer, through which the active ingredient permeates, as from a reservoir, diffuses, e.g. through a porous matrix, or undergoes osmotic exchange. A further option for a sustained-release formulation involves density exchange, e.g. in the case where the formulation alters on administrations, e.g. from microparticles to a gel, so that the active ingredient diffuses or permeates out. Ion-based resins may also be used, the active component being released by ionic exchange, and wherein the rate of release can be controlled by using cationic or anionic forms of the drug.

Preferably the formulation contains less than 20 mg dtmp, or even less than 15 mg dtmp, per unit dosage. In another embodiment, the formulation contains dtmp such that at least an initial dosage is less than 15 mg dtmp per day.

It is preferred to use a formulation in this invention that is resistant to chewing, e.g. micronised particles that are individually coated and which do not immediately release the active component on chewing, or possibly even actively discourage chewing by their consistency. The various effects etc may be due to the use of dtmp and/or the absence of ltmp.

4a

Comparative Pharmacodynamics of d-threo-methylphenidate and Racemate

The study design was based on that described by Aoyama et al, J. Pharmacobio-Dyn. 13:647-652 (1990). Male Wistar rats were dosed with methylphenidate hydrochloride or its d-isomer at nominal dose levels of

racemate: 1.5, 3, 4.5 or 6 mg base/kg body weight

d-isomer: 0.75, 1.5, 2.25 or 3 mg base/kg body weight

Blood samples were taken pre-dose, and 7 min, 15 min, 30 min, 45 min, 1 h, 1.5 h, 2 h, 3 h, 4.5 h, 6 h, 8 h post-dose. The samples were centrifuged to separate the plasma. Plasma samples were assayed for dtmp, by liquid chromatography mass spectrometry.

The results are shown in the accompanying drawing. Figure 1 gives a comparison of the AUC (area under the curve) for values, obtained from plasma concentration of dtmp, versus time, for dtmp and methylphenidate (at equivalent dtmp quantities) dosed at a range of dtmp concentrations. Both curves show non-linear kinetics, evident as a point of disjunction in each curve. As the doses administered are increased, the quantity absorbed (i.e. AUC) increases in a linear fashion, until the disjunction, when the absorbed quantity is dramatically

increased. This disjunction occurs within the clinically-relevant range (16-140 ng.h/ml in humans) for racemate dosing, but, surprisingly, is outside of this range for dtmp dosing.

5 This means that conventional dosing of the racemate, which involves increasing amounts of the drug, cannot be satisfactorily controlled. The possibility exists that a dosage will be given that is unnecessarily high.

10 Administration of dtmp has a surprising beneficial effect, in that a relatively linear dtmp AUC level in serum (lower curve) is achieved within the clinically-relevant range. The point of disjunction occurs outside the clinically-relevant range and, therefore, the flux of drug into and out of the circulatory system is more
15 controllable. This makes dtmp suitable for incorporation in a sustained release formulation.

CLAIMS

1. A sustained-release formulation of d-threo-methylphenidate (dtmp) substantially free of l-threo-methylphenidate.
2. A formulation according to claim 1, which is in dosage unit form.
3. A formulation according to claim 2, which comprises less than 20 mg dtmp per unit dosage.
4. A formulation according to claim 3, which comprises less than 15 mg dtmp per unit dosage.
5. A formulation according to any one of claims 1 to 4, wherein the formulation is in the form of a coated formulation having a coating selected from a soluble, erodable or otherwise modified coating, and insoluble coatings through which the dtmp passes when in use.
6. A formulation according to any one of claims 1 to 5, in which the dtmp is micronised.
7. A formulation according to any one of claims 1 to 6, which, on average, when administered to a sample of healthy subjects, exhibits a serum level of dtmp of at least 50% C_{max} over a period of at least 8 hours.
8. A formulation according to claim 7, wherein the period is 8 to 12 hours.
9. A formulation according to claim 7 or claim 8, wherein the serum level is less than 25% C_{max} after 12 to 16 hours.

10. A formulation according to any one of claims 1 to 9, which on administration to a healthy subject, exhibits C_{\max} of 2 to 20 ng/ml at a dosage of at least 2 mg.

11. A formulation according to any one of claims 7 to 10, wherein C_{\max} is substantially unaffected by chewing.

12. A formulation according to any one of claims 1 to 11, wherein the dtmp is in admixture with a pharmaceutically acceptable diluent or carrier.

13. A use for treating a human subject having a disorder capable of treatment with methylphenidate, of a sustained-release formulation comprising an effective amount of d-threo-methylphenidate, wherein said sustained-release formulation is substantially free of l-threo-methylphenidate, wherein said disorder is selected from the group consisting of attention-deficit hyperactivity disorder, cancer wherein the human subject is treated with narcotic analgesics, depression, compulsive shopping disorder, narcolepsy and hypersomnia.

14. The use according to claim 13, wherein at least the initial dosage is less than 15 mg d-threo-methylphenidate per day.

15. The use according to claim 13, wherein the disorder is attention-deficit hyperactivity disorder.

16. The use according to claim 13, wherein the dosage of d-threo-methylphenidate is less than 1 mg/kg/day.

17. The use according to claim 13, wherein the dosage of d-threo-methylphenidate is less than 0.5 mg/kg/day.

18. The use according to claim 13, wherein the formulation comprises less than 20 mg d-threo-methylphenidate per unit dosage.

19. The use according to claim 18, wherein the formulation comprises less than 15 mg d-threo-methylphenidate per unit dosage.

20. The use according to claim 13, wherein the formulation is in the form of a coated formulation having a coating selected from those comprising a soluble, erodible or otherwise modified coating, and those having an insoluble coating through which the d-threo-methylphenidate passes, in use.

21. The use according to claim 13, wherein said sustained-release formulation comprises d-threo-methylphenidate which is micronised.

22. The use according to claim 13, wherein said sustained-release formulation provides a serum level of d-threo-methylphenidate in a patient of at least 50% C_{max} , over a period of at least 8 hours.

23. The use according to claim 22, wherein the period is 8 to 12 hours.

24. The use according to claim 22, wherein the serum level is less than 25% C_{max} after 12 to 16 hours.

25. The use according to claim 13, wherein said sustained-release formulation provides C_{max} of 2 to 20 ng/ml in a patient at a dosage of at least 2 mg.

26. The use according to claim 22, wherein said formulation provides C_{max} of 2 to 20 ng/ml in a patient at a dosage of at least 2 mg.

27. The use according to claim 22, wherein C_{\max} is substantially unaffected by chewing.

28. A use for treating a human subject having a disorder capable of treatment with methylphenidate, a sustained-release formulation comprising an effective amount of d-threo-methylphenidate, wherein said sustained-release formulation is substantially free of l-threo-methylphenidate, and wherein said effective amount of d-threo-methylphenidate is about 16 to 140 ng.h/ml, wherein said disorder is selected from the group consisting of attention-deficit hyperactivity disorder, cancer wherein the human subject is treated with narcotic analgesics, depression, compulsive shopping disorder, narcolepsy and hypersomnia.

1/1

Chart 1

Comparison of AUC for d-isomer; d-isomer vs racemate dosing




FIG. 1

SUBSTITUTE SHEET (RULE 26)